WILLOW GROVE, Pa.--(BUSINESS WIRE)--NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy, the potential for physicians to establish therapeutic drug monitoring (TDM) of individual patients, and the assessment of drug diversion of a new pain management drug therapy. NMS Labs is the only known commercial laboratory to develop and perform a clinical quantitative assay for Milnacipran (Savella®) using the highly specific and sensitive technique of liquid chromatography/tandem mass spectrometry (LC-MS/MS).
